Strategic leadership Recent executive changes with a new CEO signaling potential strategic shifts and renewed focus on growth; engage for alignment on product roadmap, partnerships, and investor relations to accelerate commercial efforts.

Funding momentum Subscriber funding rounds totaling around $3M in 2023 and overall funding of $8.1M indicate investor interest; leverage this to secure pilot projects, early-adopter programs, and collaboration opportunities to demonstrate value.

Clinical collaboration History of collaboration with Thermo Fisher and focus on mass spectrometry-based proteomics for fetal health monitoring; target life sciences teams and hospital systems seeking advanced diagnostics and exosome-based assays.

Niche market Small team size with 2-10 employees suggests a nimble organization; offer scalable, turnkey solutions, partner-ready platforms, and clear ROI propositions tailored for tight budgets and rapid deployment.

Strategic advisory Advisory board additions from medical experts indicate emphasis on clinical validation and credibility; propose joint development opportunities, co-branded studies, and educational programs to build trust with customers.